Direct
NAV (25-Jul-24)
Returns (Since Inception)
Fund Size
₹30 Cr
Expense Ratio
0.22%
ISIN
INF209KB10C2
Minimum SIP
-
Exit Load
-
Inception Date
21 Oct 2021
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+45.20%
+45.90% (Cat Avg.)
Since Inception
+17.89%
— (Cat Avg.)
Equity | ₹29.54 Cr | 99.38% |
Others | ₹0.19 Cr | 0.62% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹6.25 Cr | 21.01% |
Dr Reddy's Laboratories Ltd | Equity | ₹2.97 Cr | 9.98% |
Cipla Ltd | Equity | ₹2.96 Cr | 9.94% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹2.64 Cr | 8.89% |
Apollo Hospitals Enterprise Ltd | Equity | ₹2.37 Cr | 7.97% |
Divi's Laboratories Ltd | Equity | ₹2.23 Cr | 7.49% |
Lupin Ltd | Equity | ₹1.49 Cr | 5.02% |
Aurobindo Pharma Ltd | Equity | ₹1.29 Cr | 4.35% |
Zydus Lifesciences Ltd | Equity | ₹1.03 Cr | 3.46% |
Torrent Pharmaceuticals Ltd | Equity | ₹0.97 Cr | 3.27% |
Alkem Laboratories Ltd | Equity | ₹0.95 Cr | 3.21% |
Glenmark Pharmaceuticals Ltd | Equity | ₹0.7 Cr | 2.35% |
Laurus Labs Ltd | Equity | ₹0.64 Cr | 2.14% |
Biocon Ltd | Equity | ₹0.59 Cr | 2.00% |
Ipca Laboratories Ltd | Equity | ₹0.58 Cr | 1.95% |
Abbott India Ltd | Equity | ₹0.56 Cr | 1.87% |
Syngene International Ltd | Equity | ₹0.49 Cr | 1.65% |
Dr. Lal PathLabs Ltd | Equity | ₹0.39 Cr | 1.32% |
Granules India Ltd | Equity | ₹0.25 Cr | 0.86% |
Metropolis Healthcare Ltd | Equity | ₹0.19 Cr | 0.65% |
Net Receivables / (Payables) | Cash | ₹0.18 Cr | 0.59% |
Clearing Corporation Of India Limited | Cash - Repurchase Agreement | ₹0.01 Cr | 0.03% |
Large Cap Stocks
59.67%
Mid Cap Stocks
34.74%
Small Cap Stocks
4.97%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹29.54 Cr | 99.38% |
Standard Deviation
This fund
--
Cat. avg.
14.65%
Lower the better
Sharpe Ratio
This fund
--
Cat. avg.
0.55
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
0.92
Higher the better
Since June 2022
Since March 2023
ISIN | INF209KB10C2 | Expense Ratio | 0.22% | Exit Load | - | Fund Size | ₹30 Cr | Age | 21 Oct 2021 | Lumpsum Minimum | - | Fund Status | Open Ended Investment Company | Benchmark | NIFTY Healthcare TR TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Flat 15% tax on realised gains (STCG - short term capital gains)
10% tax on realised gains above Rs. 1 lakh per financial year (LTCG - long term capital gains)
Note: Mutual funds are subject to capital gains taxation with surcharge and cess, based on prevailing income tax rules and investor income. Taxation applies to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹15.00 Cr | 46.7% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 1.0% | 1.0% | ₹713.42 Cr | 48.3% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹713.42 Cr | 46.3% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹29.73 Cr | 45.2% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.4% | 1.0% | ₹173.47 Cr | 45.0% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹173.47 Cr | 42.3% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2312.48 Cr | 45.8% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 2.0% | 1.0% | ₹2312.48 Cr | 43.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹638.88 Cr | 47.4% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹17.23 Cr | 44.1% |
Total AUM
₹3,61,512 Cr
Address
One World Centre, Tower 1, 17th Floor, Mumbai, 400 013
Your principal amount will be at Very High Risk